Humacyte (HUMA) Revenue (2020 - 2026)
Humacyte (HUMA) reported Revenue of $495000.0 for Q1 2026, down 4.26% year-over-year from $517000.0 in Q1 2025, and up 6.0% quarter-over-quarter from $467000.0 in Q4 2025.
Humacyte (HUMA) Revenue (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 4 years of Revenue data on file, last reported at $495000.0 in Q1 2026.
- Revenue for Q1 2026 came in at $495000.0, down 4.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 289.94% YoY), and the FY2025 annual result was $2.0 million, changed N/A from the prior year.
- Revenue improved to $495000.0 in Q1 2026 per HUMA's latest filing, from $467000.0 in the prior quarter.
- Over five years, Revenue peaked at $753000.0 in Q3 2025 and troughed at $301000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | 495,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 495,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Sep 30, 2021 | 241,000.00 |
| Sep 30, 2020 | 914,000.00 |